Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...
PD-1 and PD-L1 inhibitors are immunotherapies designed to block this mechanism, allowing the immune system to recognize and attack tumors. PD-1 is a receptor found on T-cells, while PD-L1 is its ...
They work by multiple mechanisms but most relevant to PD-1 inhibitors which work by keeping T-cells active is that MDSCs prevent T-cells from recognizing and attacking cancer cells. There is ...
There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown ... and potentially a replacement for checkpoint inhibitor standard-of-care treatments for a range of ...
Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 ...
A new cancer therapy utilising a genetically modified herpes simplex virus type 1 (HSV-1) offers hope for late-stage patients ...
Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated ...
Summit Therapeutics' ivonescimab outperforms Keytruda in Phase 3 lung cancer trials. Crucial Western market approval depends ...
Checkpoint Therapeutics, Inc. ("Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback